Eli Lilly's Foundayo (orforglipron) was prescribed 5,612 times in the United States in the third week after launch, according to IQVIA data shared by RBC Capital Markets. [1] Novo Nordisk's oral Wegovy was prescribed roughly 134,000 times the same week — its sixteenth on the market. [2] The numerator is 5,612. The denominator is 134,000. The quotient is approximately 24x: Wegovy's pill is writing twenty-four prescriptions for every Foundayo prescription in the head-to-head week. The May 5 paper carried the Wegovy pill at 113,000 weekly with Foundayo's first-month rollout running modestly. The Tuesday register is the gap.
The gap is the story, not the demographic-winter frame. RBC's Trung Huynh has bracketed Foundayo's revised 2026 sales expectation at $1.3 to $1.5 billion against earlier $5 billion projections — contingent on the pill reaching more than 90,000 weekly prescriptions by week 12 to track to a $1.4 billion run rate. [1] Foundayo's week-three at 5,612 is significantly below that trajectory. Lilly executives on the April 30 earnings call said more than 20,000 patients have been treated with Foundayo and the drug has more than 8,000 prescribers, a third of whom are new to oral GLP-1s. [3] The capture-rate gap between treated patients and IQVIA prescriptions reflects a launch still routing through LillyDirect and broad pharmacy availability that opened only April 9.
The architecture differences explain part of the gap. Foundayo requires fasting at least half an hour before eating; Novo's oral semaglutide does not. Wegovy has TrumpRx self-pay coverage at the announced $25 and $149 tiers; Foundayo had not appeared on the federal portal as of last week. Novo's launch ran into a market with pent-up demand for the first oral GLP-1; by the time Foundayo arrived in early April, that pent-up cohort had already converted. [4] BioPharma Dive's framing — "shaky week" — captures the analyst register: investors will receive the Foundayo trajectory negatively unless weeks 8 to 12 show a step-change.
The gap is the answer to the question the prior brief asked. Format mattered more than brand. Distribution and price-cap mattered more than format. Twenty-four-to-one is not a launch tied. It is a market.
-- NORA WHITFIELD, Chicago